![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Evaluation of Transporter and Cytochrome P450-Mediated Drug-Drug Interactions with the Pan Genotypic HCV NS3/4A Protease Inhibitor Voxilaprevir (GS-9857) or Sofosbuvir/Velpatasvir/Voxilaprevir and Phenotypic Probe Drugs
|
|
|
Reported by Jules Levin
17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy June 8 - 10, 2016, Washington, DC
Brian J. Kirby, James Taylor Luisa M. Stamm, Qinghua Song, Helen Wei, Yizhao Li, Dina Alhelawe, K-H John Ling, and Anita Mathias
Gilead Sciences, Foster City, CA
![Clin1](../images/062916/062916-2/Clin1.gif)
![Clin2](../images/062916/062916-2/Clin2.gif)
![Clin3](../images/062916/062916-2/Clin3.gif)
![Clin4](../images/062916/062916-2/Clin4.gif)
![Clin5](../images/062916/062916-2/Clin5.gif)
![Clin6](../images/062916/062916-2/Clin6.gif)
![Clin7](../images/062916/062916-2/Clin7.gif)
![Clin8](../images/062916/062916-2/Clin8.gif)
![Clin9](../images/062916/062916-2/Clin9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|